AR and prostate carcinoma: Our results in the preventative setting further suggest that once safety for these vaccines is established, it may be more effective to utilize these vaccines at earlier timepoints prior to the development of resistance, as a means to elicit AR-specific T cells against prostate cancer, as well as prevent the emergence of resistant AR-V7+ prostate cancer cells.